Trial reportJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2016
Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.
Trial report in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Trial
- Prognostic significance of dobutamine stress echocardiography in patients with chronic kidney disease and known or suspected coronary artery disease: a 5-year follow-up study.Heart and vessels · 2025Article
- Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2022: single photon emission computed tomography.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Review
- The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Cardiac imaging for the assessment of patients being evaluated for kidney transplantation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
- The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The Prognostic Value of MPI in CKD: Can we do better?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Heart rate and 123I-MIBG in heart failure with preserved ejection fraction: More variability and slower washout-A secret recipe for better survival.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Myocardial stunning by gated SPECT: An old tool reinvented in a stunning turn.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- The prognostic value of heart rate response during vasodilator stress myocardial perfusion imaging in patients with end-stage renal disease undergoing renal transplantation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Risk stratification for renal transplantation: A role for heart rate response?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Adverse effects associated with regadenoson myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes.European journal of nuclear medicine and molecular imaging · 2018Article
- The heart rate response to regadenoson in patients with atrial fibrillation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Review
- Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Impact of integrating heart rate response with perfusion imaging on the prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Review of cardiovascular imaging in the journal of nuclear cardiology in 2016: Part 2 of 2-myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Review
- Multi-modality imaging: Bird's eye view from the 2016 American Heart Association Scientific Sessions.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlunted heart rate response (HRR) to vasodilator stress agents is associated with worse outcomes. There are limited data assessing the effect of impaired HRR to regadenoson among patients with end-stage renal disease (ESRD) undergoing stress myocardial perfusion imaging (MPI).
methodsWe prospectively followed patients with ESRD enrolled in the ASSUAGE and ASSUAGE-CKD trials. HRR was defined as 100*(peak stress heart rate-resting heart rate)/resting heart rate. Study cohort was dichotomized to blunted and normal HRR groups according to an established median HRR value <28% or ≥28%, which were propensity-score matched based on 22 clinical and imaging covariates. The Primary endpoint was all-cause death. The secondary cardiac-specific endpoints included: (1) the composite endpoint of cardiac death or myocardial infarction; (2) the composite endpoint of cardiac death, myocardial infarction, or late (>90 days) coronary revascularization.
resultsThere were 303 patients followed for 35 ± 10 months. In the entire cohort, there was a stepwise increase in the rates of death and all secondary endpoints with worsening HRR (P values ≤.001). Blunted HRR (<28%) was associated with increased risk of death (unadjusted hazard ratio 4.10 [1.98-8.46], P < .001) and all secondary endpoints (P ≤ .001). After multivariate adjustment, HRR remained an independent predictor of mortality and secondary endpoints whether used as continuous or dichotomous variable, and added incremental prognostic value for all-cause death (P = .046). Blunted HRR was associated with increased event rate among patients with normal myocardial perfusion (P = .001) and abnormal perfusion (P = .053). In the propensity-matched cohort of 132 patients (66 in each group), blunted HRR was associated with significant increase in all-cause death (21% vs. 5%, HR 5.09 [1.46-17.7], P=.011), and similarly for the secondary endpoints.
conclusionBlunted HRR (<28%) to regadenoson is a strong and independent predictor of death and cardiovascular events in patients with ESRD and adds incremental prognostic value.
Indexed as
Identifiers
26293358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.